Key facts
- It has raised $3.6M; the latest was Seed Round ($3.1M) in Apr 2025.
- Notable investors include Y Combinator, NVO Capital, Pags Group.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Maven Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Maven Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Maven Bio
Developer of a biopharma commercial intelligence platform designed to improve drug approval rates. The company's platform allows stakeholders of all disciplines to evaluate therapeutic opportunities and provide information on commercial failure rates, enabling biopharma consultants, investors, and in-house teams to reduce manual work and make better business decisions.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2023
- Employees
- 7
- Website
- mavenbio.com/
- Ownership
- Privately Held (backing)
Maven Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Maven Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Maven Bio in its N-PORT filings yet. We sweep new filings monthly.